CYTK Stock Price, Chart, Stats & News

Cytokinetics, Incorporated
Save
9.80B
Market cap
–
Current P/E
117.65x
Forward P/E
CYTK chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -22.29% |
Operating margin | -695.44% |
Pretax margin | -891.60% |
Net margin | -891.60% |
Effective tax rate | – |
ROA | -55.10% |
ROE | 172.91% |
D/E | -1.95x |
Interest coverage ratio | -5.89x |
CYTK valuation
P/E | – |
P/S | 87.43x |
P/B | -11.56x |
P/CF | -14.95x |
P/FCF | -14.39x |
P/OCF | -14.95x |
PEG | 2.78x |
EV multiple | -10.40x |
About
Cytokinetics, Incorporated is an advanced biopharmaceutical company dedicated to the research, development, and commercialization of therapies that modulate muscle function. These novel compounds aim to address debilitating diseases. The core of their pipeline consists of small molecule drug candidates specifically designed to influence muscle performance and contraction at a fundamental level.
Similar securities
Based on sector and market capitalization
Report issue











